+
Ipsen announces completion of acquisition of Albireo, strengthening rare disease portfolio with promising therapeutics for pediatric and adult rare liver diseases.
We are harnessing the power of bile acid modulation to pursue potential new treatment options to improve the lives of people living with liver disease.
Learn MorePatients are the driving force behind everything that we do. Learn more about the burden of cholestatic liver diseases.
Learn MoreWe are committed to our employees and patients as well as the communities that we live and work in.
Learn MoreIf you are an exceptional teammate who is committed to excellence, Albireo is the right place for you.